We are live on ! Find out more
HRTX icon

Heron Therapeutics
HRTX

186 hedge funds and large institutions have $621M invested in Heron Therapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 75 increasing their positions, 47 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

202% more call options, than puts

Call options by funds: $7.75M | Put options by funds: $2.57M

60% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 47

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

7% less funds holding

Funds holding: 200 → 186 (-14)

9.13% less ownership

Funds ownership: 115.41% → 106.28% (-9.1%)

39% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 36

42% less capital invested

Capital invested by funds: $1.07B → $621M (-$453M)

Holders
186
Holders Change
-14
Holders Change %
-7%
% of All Funds
2.93%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
22
Increased
75
Reduced
47
Closed
36
Calls
$7.75M
Puts
$2.57M
Net Calls
+$5.18M
Net Calls Change
+$3.05M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$38.3M
2
Bank of America
Bank of America
North Carolina
+$9.23M
3
Morgan Stanley
Morgan Stanley
New York
+$8.62M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$5M
5
OCM
Orchard Capital Management
Illinois
+$4.4M

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$75.6M
2
TCM
Tang Capital Management
California
-$29.7M
3
SI
Sofinnova Investments
California
-$21.4M
4
RCAMU
Rothschild & Co Asset Management US
Connecticut
-$12.6M
5
Citadel Advisors
Citadel Advisors
Florida
-$10.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$4.09M +$139K +19,049 +3%
PHS
27
Pekin Hardy Strauss
Illinois
$3.42M +$205K +28,025 +5%
WP
28
Woodline Partners
California
$3.26M +$83.1K +11,356 +2%
N
29
Nuveen
North Carolina
$2.86M -$1.18M -161,797 -22%
PP
30
PDT Partners
New York
$2.86M +$3.19M +436,461 +689%
NAM
31
Nexpoint Asset Management
Texas
$2.85M – – –
KBC Group
32
KBC Group
Belgium
$2.72M – – –
Susquehanna International Group
33
Susquehanna International Group
Pennsylvania
$2.27M +$953K +130,178 +49%
AllianceBernstein
34
AllianceBernstein
Tennessee
$2.17M +$1.83M +250,300 +194%
Dimensional Fund Advisors
35
Dimensional Fund Advisors
Texas
$1.82M -$133K -18,176 -5%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$1.74M +$43K +5,882 +2%
HWAM
37
Hennion & Walsh Asset Management
New Jersey
$1.62M -$88.5K -12,098 -4%
BNP Paribas Financial Markets
38
BNP Paribas Financial Markets
France
$1.47M +$765K +104,604 +68%
UBS Group
39
UBS Group
Switzerland
$1.34M -$623K -85,137 -27%
Swiss National Bank
40
Swiss National Bank
Switzerland
$1.31M +$112K +15,300 +7%
DADC
41
D.A. Davidson & Co
Montana
$1.27M +$137K +18,680 +9%
Ameriprise
42
Ameriprise
Minnesota
$1.27M +$188K +25,665 +13%
PPA
43
Parametric Portfolio Associates
Washington
$1.24M +$302K +41,299 +24%
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
$1.22M +$702K +95,900 +81%
Citadel Advisors
45
Citadel Advisors
Florida
$1.21M -$10.8M -1,481,347 -88%
CM
46
CM Management
Florida
$1.14M +$1.1M +150,000 +300%
Deutsche Bank
47
Deutsche Bank
Germany
$1.11M -$1.42M -194,535 -50%
MF
48
Magnetar Financial
Illinois
$1.05M +$133K +18,192 +11%
Fisher Asset Management
49
Fisher Asset Management
Washington
$1.03M +$361K +49,387 +38%
ECM
50
ExodusPoint Capital Management
New York
$958K +$732K +100,039 +148%
1
2
3 4 5

HRTX Hedge Fund Activity: Q1 2022 in Review

186 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2022, worth a combined $621M — down 42% from $1.07B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of HRTX and 22 opened new positions — a net loss of 14 holders — while 47 trimmed existing stakes and 75 added.

The largest buyer was State Street, adding an estimated $38.3M. The largest seller was UBS O'Connor, exiting entirely with an estimated $75.6M sold.

  • 186 institutional investors held Heron Therapeutics (HRTX) as of Q1 2022, down from 200 in Q4 2021.
  • Funds reported $621M of Heron Therapeutics stock for Q1 2022, down 42% quarter-over-quarter.
  • 22 funds opened new Heron Therapeutics positions in Q1 2022 and 36 closed out, a net change of -14 holders.
  • The largest Heron Therapeutics buyer in Q1 2022 was State Street, an estimated $38.3M added.
  • The largest Heron Therapeutics seller in Q1 2022 was UBS O'Connor, an estimated $75.6M sold.

Based on aggregated 13F filings for Q1 2022.